Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

MOUNTAINEER and DESTINY-CRC01 Trials Expand Second-Line Options for HER2+ mCRC

April 15th 2023

Alaa Muslimani, MD, discusses the significance of the phase 2 DESTINY-CRC01 and MOUNTAINEER-03 trials on HER2-positive metastatic colorectal cancer treatment in the second line, efforts to expand the use of these agents in earlier disease settings, and the need for more robust clinical data and larger investigations for this population.

Role of Circulating Tumor DNA Testing in Colorectal Cancer

April 14th 2023

In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.

Role of HER2 Expression in Colorectal Cancer

April 14th 2023

A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.

Actionable Subsets of Patients With CRC Drive Progress

April 12th 2023

With an overall 5-year survival rate of under 15% in patients with metastatic colorectal cancer, investigators have sought to parse mutational analyses to increase gains.

Dr Foote on the Use of Tucatinib Plus Trastuzumab in HER2-Amplified mCRC

April 10th 2023

Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.

Low RNA Expression of RAD51, BRCA1 Associated With Prolonged OS in HRP CRC

April 8th 2023

Daniel Walden, MD, discusses the goal of analyzing RNA expression of wild-type HR genes in CRC, the importance of evaluating the benefit of chemotherapeutic approaches in patients with HRP CRC based on RNA expression levels, and the next steps for validating and implementing these findings in clinical practice.

Pembrolizumab/Lenvatinib Combo Misses OS End Points in Select Advanced Melanoma and mCRC

April 7th 2023

The phase 3 LEAP-003 and LEAP-017 trials evaluating pembrolizumab plus lenvatinib did not meet their primary end points of overall survival in select patients with unresectable or metastatic melanoma and metastatic colorectal cancer, respectively.

Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?

April 7th 2023

In an era of genomics, proteomics, and immunology a biomarker as simple as anatomy may be useful in terms of predicting responses in patients with colorectal cancer.

Colorectal Cancer: An Overview on Molecular Profiling

April 7th 2023

Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.

Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes

April 7th 2023

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.

Dr Hays on Treating Patients With HER2+ CRC

April 6th 2023

John L. Hays, MD, PhD, discusses advances in treating patients with HER2-positive colorectal cancer.

Effective Detection of MRD May Support Earlier Implementation of ctDNA Testing in CRC

April 6th 2023

Stacey A. Cohen, MD, discusses the advantages and limitations of ctDNA as a biomarker for detecting minimal residual disease , real-world data on the relationship between fluctuating cfDNA levels and ctDNA detection, and how implementing ctDNA testing earlier to identify minimal residual disease could serve as a prognostic tool in clinical practice.

Metastatic Colorectal Cancer: Future Directions in Care

April 3rd 2023

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

FDA Approval Sought for Fruquintinib in Refractory Metastatic Colorectal Cancer

March 31st 2023

A new drug application seeking the approval of fruquintinib for use in the treatment of patients with refractory metastatic colorectal cancer has been submitted to the FDA.

Encouraging Data Pave the Way for New Standards in CRC

March 29th 2023

As the development of systemic treatments for metastatic colorectal cancer move toward precision therapy, guidelines have adjusted to integrate decisions based on molecular drivers.

Severity of Patient-Reported Symptom Burden Remains Low and Stable After Adjuvant Systemic Treatment in CRC

March 29th 2023

Although some patients with stage II/III colorectal cancer were at an increased risk of severe symptoms and deterioration over time, patient-reported symptoms showed that those with newly diagnosed disease generally reported a low symptom burden that remained stable or improved after receiving adjuvant systemic therapy, according to a retrospective analysis.

Dr Muslimani on the Implications of the MOUNTAINEER Trial in HER2+ mCRC

March 27th 2023

Alaa Muslimani, MD, discusses the unmet needs for patients with HER2-positve metastatic colorectal cancer and highlights the implications of the phase 2 MOUNTAINEER trial in this patient population.

Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials

March 27th 2023

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

Combination IO/TKI Strategies in Metastatic Colorectal Cancer

March 27th 2023

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

Clinical Trials in Metastatic Colorectal Cancer: Combination IO Therapy

March 20th 2023

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.